User:Mr. Ibrahem/Pegunigalsidase alfa

Pegunigalsidase alfa, sold under the brand name Elfabrio, is a medication used to treat Fabry disease. It is given by gradual injection into a vein.

Common side effects include infusion-related reactions, allergic reactions, and weakness. Other side effects may include kidney problems, specifically membranoproliferative glomerulonephritis. It works as enzyme replacement therapy, being a modified form of α-galactosidase-A.

Pegunigalsidase alfa was approved for medical use in Europe and the United States in 2023. It is made by recombinant DNA technology. As of mid 2023 the cost was unclear in the United States.